Special Issue

Pharmacological Activities of Schiff Bases and/or Their Metal Complexes

Message from the Guest Editor

It is well known that Schiff bases were first discovered by the German chemist noble prize winner Hugo Schiff and today are among the most widely used organic compounds. They can be found in nature and are also synthesized in the laboratory, and they are characterized by the presence of a double-bond-linking carbon and nitrogen atoms. Schiff bases are considered privileged ligands since they can coordinate strongly to metal ions and have the ability to form very stable complexes with transition metals. Schiff bases as well as their metal. complexes present a great variety of biological activities. It has been found that they may possess antibacterial, antimicrobial, antifungal, antibiofilm, antimalarial, antioxidant, antiproliferative, antiinflammatory, antiviral, anti-analgetic, or antipyretic properties. The also find use in other potential industrial applications, for example, in sensors and photovoltaic materials. In this Special Issue, our goal is to gather experts in the field of Schiff bases and to gain more insight into the recent pharmacological aspects of these fascinating complexes, as well as of their coordination compounds with metal ions.

Guest Editor

Dr. Ariadni Zianna

Laboratory of Inorganic Chemistry, Department of Chemistry, Aristotle University of Thessaloniki, Thessaloniki, Greece

Deadline for manuscript submissions

closed (25 January 2024)



Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/141172

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/ pharmaceuticals





Pharmaceutica

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals*.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

